NCT03951168 (hefdm) is a NA clinical trial of Routine Management in Diabetes Mellitus, sponsored by First Affiliated Hospital Xi'an Jiaotong University.

Who is sponsoring NCT03951168?

NCT03951168 is sponsored by First Affiliated Hospital Xi'an Jiaotong University.

What drugs are being tested in NCT03951168?

Interventions in NCT03951168: Routine Management, Standardized Management.

What condition does NCT03951168 study?

NCT03951168 studies Diabetes Mellitus.

Is NCT03951168 still recruiting?

NCT03951168 is currently completed. Last updated 18 November 2020.

Last reviewed 2020-11-18 · How we verify

NCT03951168: hefdm

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Health Education for Diabetes Mellitus

Completed NA Last updated 18 November 2020

What this trial tests

NA trial testing Routine Management in Diabetes Mellitus in 206 participants. Completed in 30 June 2020.

Timeline

1 July 2019

Primary endpoint
30 June 2020

30 June 2020

Quick facts

Lead sponsor	First Affiliated Hospital Xi'an Jiaotong University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	health services research
Enrollment	206
Start date	1 July 2019
Primary completion	30 June 2020
Estimated completion	30 June 2020
Sites	1 location across China

Drugs / interventions tested

Routine Management — full drug profile →
Standardized Management

Conditions studied

Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

First Affiliated Hospital Xi'an Jiaotong University

Who can join

Adults 18 to 70, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Through the construction and study of standardized diabetic health education management model. Routine diabetes health education management model was used in control group and standardized diabetes mellitus health education management model was used in intervention group. The changes of diabetic knowledge, self-management ability, quality of life,patient empowerment, HbA1c, and other metabolic indexes were observed.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

[Health education in diabetes mellitus].
Isla Pera P. · · 1990 · PMID 2377880 · DOI 10.31525/ct1-nct03951168

Verify or expand the search:

Other trials of Routine Management

Trials testing the same drug.

NCT07097818 — Efficacy of Glycemic Improvement Project (GLITTER Study) in Type 1 Diabetes-GLITTER Study 2 · NA · recruiting
NCT06652750 — Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices · NA · recruiting

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT07392437 — Prevalence of Diabetes-related Distress Among Patients Living With Type 2 Diabetes in a University Hospital Center and I · NA · recruiting
NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
NCT07425275 — Integrated Oral Care Intervention for Xerostomia in Diabetes Patients · NA · recruiting
NCT06918977 — Improving Glycemic Control With Telemedicine and Smart Insulin Pens · NA · recruiting

Other First Affiliated Hospital Xi'an Jiaotong University trials

Trials by the same sponsor.

NCT07389460 — Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND) · Phase 3 · not yet recruiting
NCT07170176 — Effects of PFO Closure on Glymphatic Function and Clinical Symptoms in Patients With Migraine · NA · recruiting
NCT07168291 — Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · EARLY_PHASE1 · not yet recruiting
NCT06775782 — Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke Due to Large Artery Atherosclerosis · NA · recruiting
NCT07266467 — Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Dis · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03951168 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by First Affiliated Hospital Xi'an Jiaotong University
Last refreshed: 18 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03951168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing